129 related articles for article (PubMed ID: 28179964)
21. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
Leone JP; Leone J; Zwenger AO; Iturbe J; Leone BA; Vallejo CT
Eur J Cancer; 2017 Mar; 74():17-25. PubMed ID: 28335884
[TBL] [Abstract][Full Text] [Related]
22. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
Brennan DJ; Jirstrom K; Kronblad A; Millikan RC; Landberg G; Duffy MJ; Rydén L; Gallagher WM; O'Brien SL
Clin Cancer Res; 2006 Nov; 12(21):6421-31. PubMed ID: 17085655
[TBL] [Abstract][Full Text] [Related]
23. Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy.
Bernhardt D; Adeberg S; Bozorgmehr F; Opfermann N; Hoerner-Rieber J; König L; Kappes J; Thomas M; Herth F; Heußel CP; Warth A; Debus J; Steins M; Rieken S
J Neurooncol; 2017 Aug; 134(1):205-212. PubMed ID: 28560661
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes in patients with brain metastases from breast cancer treated with single-session radiosurgery or whole brain radiotherapy.
Mix M; Elmarzouky R; O'Connor T; Plunkett R; Prasad D
J Neurosurg; 2016 Dec; 125(Suppl 1):26-30. PubMed ID: 27903186
[TBL] [Abstract][Full Text] [Related]
25. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
26. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
[TBL] [Abstract][Full Text] [Related]
27. Bone metastases in breast cancer: Frequency, metastatic pattern and non-systemic locoregional therapy.
Steinauer K; Huang DJ; Eppenberger-Castori S; Amann E; Güth U
J Bone Oncol; 2014 May; 3(2):54-60. PubMed ID: 26909298
[TBL] [Abstract][Full Text] [Related]
28. Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression?
Rack B; Janni W; Gerber B; Strobl B; Schindlbeck C; Klanner E; Rammel G; Sommer H; Dimpfl T; Friese K
Breast Cancer Res Treat; 2003 Nov; 82(2):83-92. PubMed ID: 14692652
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
Sanpaolo P; Barbieri V; Genovesi D
Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
[TBL] [Abstract][Full Text] [Related]
31. Gamma Knife surgery for metastatic brain tumors from primary breast cancer: treatment indication based on number of tumors and breast cancer phenotype.
Matsunaga S; Shuto T; Kawahara N; Suenaga J; Inomori S; Fujino H
J Neurosurg; 2010 Dec; 113 Suppl():65-72. PubMed ID: 21121788
[TBL] [Abstract][Full Text] [Related]
32. The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases.
Darlix A; Hirtz C; Thezenas S; Maceski A; Gabelle A; Lopez-Crapez E; De Forges H; Firmin N; Guiu S; Jacot W; Lehmann S
BMC Cancer; 2019 Jan; 19(1):110. PubMed ID: 30700265
[TBL] [Abstract][Full Text] [Related]
33. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
[TBL] [Abstract][Full Text] [Related]
34. Clinical features and survival analysis of different subtypes of patients with breast cancer brain metastases.
Bai B; Yuan ZY; Liu DG; Teng XY; Wang SS
Chin J Cancer; 2010 Apr; 29(4):413-9. PubMed ID: 20346218
[TBL] [Abstract][Full Text] [Related]
35. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease.
Colomer R; Ruibal A; Salvador L
Cancer; 1989 Oct; 64(8):1674-81. PubMed ID: 2790682
[TBL] [Abstract][Full Text] [Related]
36. Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.
Ulas A; Bilici A; Durnali A; Tokluoglu S; Akinci S; Silay K; Oksuzoglu B; Alkis N
Tumour Biol; 2016 Jan; 37(1):1131-40. PubMed ID: 26276360
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis.
Altundag K; Bondy ML; Mirza NQ; Kau SW; Broglio K; Hortobagyi GN; Rivera E
Cancer; 2007 Dec; 110(12):2640-7. PubMed ID: 17960791
[TBL] [Abstract][Full Text] [Related]
38. Survival after palliative radiotherapy in geriatric cancer patients.
Nieder C; Angelo K; Haukland E; Pawinski A
Anticancer Res; 2014 Nov; 34(11):6641-5. PubMed ID: 25368269
[TBL] [Abstract][Full Text] [Related]
39. Bone density as a marker for local response to radiotherapy of spinal bone metastases in women with breast cancer: a retrospective analysis.
Foerster R; Eisele C; Bruckner T; Bostel T; Schlampp I; Wolf R; Debus J; Rief H
Radiat Oncol; 2015 Mar; 10():62. PubMed ID: 25884703
[TBL] [Abstract][Full Text] [Related]
40. [Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases].
Cai Y; Wang WL; Xu B; Zhu GY; Zhang SW
Ai Zheng; 2006 Nov; 25(11):1419-22. PubMed ID: 17094913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]